Verenium Corp - VRNM - reported an agreement with Tate & Lyle for the use of one of its proprietary enzyme products in the development of novel food ingredients. Under the terms of the agreement, Verenium receives $1.5 million in near term milestone payments, revenues from enzyme product sales, and a royalty on Tate & Lyle’s future sales.
